News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Johnson & Johnson, Vanderbilt University in Unusual $10M Schizophrenia Drug Deal
January 9, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Johnson & Johnson has made an unusual $10 million deal with Vanderbilt University, whose researchers will work on development of a potential new schizophrenia treatment, all the way up to creating a compound ready for testing in people.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Johnson & Johnson Family of Companies
MORE ON THIS TOPIC
Venture capital
Lilly-Backed China Startup Debuts With $68.7M Seed to Advance Next-Gen T Cell Engagers
March 18, 2026
·
2 min read
·
Tristan Manalac
Funding
R1 Leads Busy Fundraising Day With $77.5M Series A Raise for Kidney Disease
March 18, 2026
·
2 min read
·
Tristan Manalac
Layoff Tracker
Bicycle Downsizes by 30% After Deprioritizing Lead Program
March 18, 2026
·
37 min read
·
BioSpace Editorial Staff
Deals
Astellas Divorces CytomX Despite Positive Phase 1 Data for Antibody Platform
March 17, 2026
·
2 min read
·
Tristan Manalac